EyePoint Reports Q4 Results, Highlights $300M+ Cash Runway and Mid-2026 Wet AMD Trial Data
EYPT has more than doubled off its 52-week low of $3.91.
Summary
EyePoint, Inc. announced its fourth quarter and full-year 2025 financial results alongside significant corporate developments. The company reported a strong cash position of over $300 million, extending its financial runway into Q4 2027, which is a material positive for a clinical-stage biotechnology firm. This update also confirmed that pivotal Phase 3 data for DURAVYU in wet AMD is anticipated to begin in mid-2026, a key upcoming catalyst. Additionally, a Chief Commercial Officer was appointed to spearhead launch readiness for DURAVYU. While the financial results included increased net losses, the comprehensive update emphasizes strategic progress and robust financial stability, positioning the company for future milestones. Traders will closely watch the mid-2026 data readouts for DURAVYU in wet AMD.
At the time of this announcement, EYPT was trading at $18.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.91 to $19.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.